In this double-blind, randomized trial, which lasted for 2 years, the authors investigated
the efficacy of calcium dobesilate on diabetic retinopathy. 68 patients (51 on the
active substance, 17 on placebo) participated in the study. The statistical analysis
of the results indicate that calcium dobesilate acts as a potent angioprotector, capable
of preventing both intra and extraretinal hemorrhages. The drug also lowers the incidence
of exudate formation and improves visual acuity.